Ten-year evolution of statin eligibility and use in a population-based cohort: the CoLaus|PsyCoLaus study

Details

Ressource 1 Under indefinite embargo.
UNIL restricted access
State: Public
Version: After imprimatur
License: Not specified
Serval ID
serval:BIB_B8CC555572DB
Type
A Master's thesis.
Publication sub-type
Master (thesis) (master)
Collection
Publications
Institution
Title
Ten-year evolution of statin eligibility and use in a population-based cohort: the CoLaus|PsyCoLaus study
Author(s)
ROCHAT M.
Director(s)
VAUCHER J.
Institution details
Université de Lausanne, Faculté de biologie et médecine
Publication state
Accepted
Issued date
2021
Language
english
Number of pages
26
Abstract
"Background
Studies on management of dyslipidemia show that eligible individuals are undertreated and that a large proportion of them do not reach LDL-cholesterol target levels.
Aim
Using recent data from a population-based cohort, we assessed the use of statins, including their intensity, in primary and secondary prevention.
Methods
Data from the CoLaus IPsyColaus study, involving 4,655 participants at baseline (2003-2006) and 3,587 at 10-year follow-up (2014-2017) were available. We estimated 10-year cardiovascular risk
using SCORE and PCE equations. We first determined eligibility for statins and adherence to recommendations in primary prevention. Additionally, we assessed the prevalence of statin users in 2014-2017 in people free from ASCVD at baseline and who developed an ASCVD during the follow-up (secondary prevention).
Results
During follow-up, 219 people developed a first ASCVD. ln primary prevention, statin use in eligible individuals according to SCORE was 25.9% in 2003-2006 and 35.9% in 2014-2017. Statin use in eligible individuals according to PCE was 24.0% in 2003-2006 and 26.3% in 2014-2017. Following ESC guidelines, only 28.2% of treated people achieved LDL-C target levels in 2014-2017 (15.8% in 2003- 2006), women less frequently attaining goals. Only 18% of individuals used high-intensity statins in 2014-2017, women less often receiving them (14% vs. 22%}. ln secondary prevention, only 74% of eligible individuals were using statins.
Conclusion
Based on contemporaneous data, management of dyslipidemia is suboptimal in both primary and secondary preventions, especially with an underuse of high-intensity statins with adapted posology.
Women are less frequently treated and, if treated, receive high-intensity treatment less frequently."
Keywords
"Cardiovascular, prevention, risk score, statin, guidelines
Create date
04/10/2023 15:28
Last modification date
05/10/2023 6:59
Usage data